Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Date:8/3/2010

THE WOODLANDS, Texas, Aug. 3 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its second quarter 2010 financial results on Monday, August 9, 2010 before the financial markets open.  Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 92435005.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through August 16, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
2. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
3. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
4. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
5. Lexicon to Present at BIO International Convention
6. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
7. Lexicon Announces Proposed $95 Million Common Stock Offering
8. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
9. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
10. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
11. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
(Date:5/10/2017)... Ill. , May 10, 2017 Radiology ... today; unfortunately its costs have also spiraled to the ... being sent to radiology than ever before as the ... diagnosis.  For a patient with lower back pain an ... no anatomical reason for pain, resulting in entirely different ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... implants in Bayside, NY, who have now spent 10 years as clinical instructors ... York University (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge ...
(Date:5/24/2017)... NV (PRWEB) , ... May 24, 2017 , ... ... NV, recently completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education ... to learning the latest advancements in his field by attending numerous CE courses ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... offering holistic pediatric dentistry options for its patients on Long Island, New York. ... entire physical well being, and is one of the biggest trends in dentistry ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... sleep diagnostics sensors, announced today it had completed the first phase of building ... of domestic and rest of world (ROW) authorized dealers specializing in polysomnography accessories. ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... in North Carolina have remained steady since 2009, according to a Workers Compensation ... , The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
Breaking Medicine News(10 mins):